AroCell AB, in partnership with Corgenix, has recently announced that AroCell’s TK 210 ELISA kit has been approved and validated for Thymidine Kinase 1 (TK1) measurement for clinical and preclinical usage in human samples, at the laboratory facility of Corgenix in Colorado, U.S.
Seemingly, this collaboration would be making the patented biomarker assay of AroCell available as in the already present AroCell TK 210 ELISA kit and as a service, for measuring TK1 protein concentrations in human serum samples.
AroCell said this will offer maximum flexibility for their customers in the U.S. In addition, it also expands the services that Corgenix provides in their CAP compliant Clinical Laboratory Improvement Amendments-lab (CLIA-lab).
Sources familiar with the matter informed that Corgenix boasts of more than 25 years of experience in the In Vitro Diagnostic (IVD) industry, focusing on product manufacturing, distribution, development, regulation, and contract services with a CAP/CLIA-lab that is based in Colorado, U.S.
A CAP or CLIA-lab is a medical laboratory where human sample testing takes place and that follows the CAP standards in U.S. The AroCell TK 210 ELISA of assay validation has been completed successfully and also added to the test menu of Corgenix’s laboratory, sources added.
According to Kelly R Pitts, Ph.D., Chief Scientific Officer and General Manager of Corgenix stated that the Corgenix Clinical Laboratory provides clients a structured environment for understanding comprehend distinctive biomarkers in their sample sets.
Dr. Pitts said adding assay of the AroCell TK1 to the company’s menu further increases their ability to help those clients that are expanding the limitations of therapeutic approaches in oncology and beyond. AroCell’s TK 210 kit is presently the only test for measuring the concentrations of TK1 protein in serum blood, besides being CE marked in EU/ESS.
Sources further reported that Thymidine Kinase 1 is a remarkable tumor biomarker and TK1 protein assays accessible in a CLIA registered lab in the U.S. will make its application simpler and more convenient for the pharmaceutical industry and clinical research.
